Foundation for innovation
in Cardiometabolism and Nutrition

Recherche médicale cardiométabolisme IHU ICAN

ICAN Omics metabolomics

What is metabolomics?

Metabolomics is the exhaustive study of all small organic molecules (less than 1000 Da). Metabolites and the associated biochemical reactions form a common basis for the proper functioning of all organisms, with some specific features in certain cases.

It is therefore possible to analyse the metabolites contained in biological matrices (plasma, serum, tissues, faeces, etc.) in order to identify deregulations, compared with a control population for example.

The metabolism is based on a fragile balance: it responds constantly to recurrent external stimuli such as food, or to more specific stimuli such as the appearance of a pathology.

The ultimate aim is to detect and quantify these metabolites that are outside the norm, in order to improve the prevention and/or treatment of various diseases (better stratification of patients for more personalised treatment, adaptation of their lifestyle, etc.).

The ICAN Omics metabolomics platform

The expertise of the ICAN Omics metabolomics platform is to offer different approaches to help develop precision medicine.

With a simple blood test and a signature including various specific metabolites, it is possible to improve the prevention and/or treatment of various pathologies.

  • Our approaches are based on the profiling of a large number of metabolites using multidisciplinary skills combining bioinformatics, statistical tools and biochemical databases to interpret the results using a high-resolution mass spectrometer coupled with chromatographic systems.
  • Our approaches are suited to the search for candidate biomarkers for diagnostic, prognostic and treatment response purposes.
  • Other so-called targeted (or profiling) approaches are based on published or known markers in order to verify and/or validate their relevance to a disease, or to represent a specific signature of a population.

Our expertise

  • Metabolome studies
  • Acquisition and interpretation of metabolomic profiles
  • Analysis and quantification of several families of metabolites
  • Advice on and implementation of metabolomic assays
  • Annotation, identification and structural elucidation of metabolites (HRMS, MS/MS)
  • Development and implementation of custom methods

Certifications

IBiSA label renewed in 2023. Find out more.

Targeted approach

  • Absolute quantification of amino acids, tryptophan pathway, choline metabolism pathway (TMAO, Choline…), short-chain fatty acids (SCFAs), bile acids (in dvlpt)

Non-targeted approach

  • Study of the global metabolome using several chromatographic methods
  • Detection of over 200 metabolites in biofluids (plasma-serum)

Profiling method

Detection and relative quantification of compounds linked to the microbiota and belonging to the

  • Method 1: amino acids, organic compounds, phenols, methylamines and some indoles
  • Method 2: Acylcarnitines, free fatty acids and bile acids

Biological study matrices

  • Serum-Plasma, CSF, urine, faeces, cecum, PBMC and glial cells.
  • Other matrices under pilot study conditions

Contact the operational manager for further information – Farid Ichou f.ichou@ihuican.org

Steering committee

Philippe Lesnik (DR, UMR ICAN 1166)

Scientific Director

Farid Ichou (IR, ICAN)

Operational manager

Scientific Committee

  • Dr F. Fenaille (CEA)
  • Dr I. Gomperts Boneca (Institut Pasteur)
  • Dr F. Lamari (APHP)
  • Dr W. Le Goff (UMR ICAN 1166)
  • Pr F. Mochel (ICM)

Access conditions

Access to our platform is via an analytical request.

The procedure after receipt of the request form is as follows:

  • Assessment of the project and preparation of a pricing proposal
  • Validation of the specifications and signature of a quotation/agreement
  • Receipt of samples
  • Carrying out the work in accordance with the specifications (or estimate)
  • Presentation of the final study report

Contact

Farid Ichou (IR, ICAN)

f.ichou@ihuican.org

01 84 82 77 68

47-48 bd de l’hôpital
75013 Paris, France
ICAN – bât E3M – 6th floor

Major publications ICAN Omics

Latest publications

26/03/2025

MAIT Cells Promote Cholesterol Excretion Pathways Mitigating Atherosclerosis

28/10/2024

Multiple Sclerosis Patient Macrophages Impaired Metabolism Leads to an Altered Response to Activation Stimuli

12/03/2024

Perturbation and resilience of the gut microbiome up to 3 months after β-lactams exposure in healthy volunteers suggest an important role of microbial β-lactamases

15/12/2023

Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations

17/10/2023

Fluid shear stress triggers cholesterol biosynthesis and uptake in inner medullary collecting duct cells, independently of nephrocystin-1 and nephrocystin-4

01/10/2023

Deleterious functional consequences of perfluoroalkyl substances accumulation into the myelin sheath

01/09/2023

Impaired metabolism predicts coronary artery calcification in women with systemic lupus erythematosus

23/08/2023

Identification of the specific molecular and functional signatures of pre-beta-HDL: relevance to cardiovascular disease

27/07/2023

Integrated omics approach for the identification of HDL structure-function relationships in PCSK9-related familial hypercholesterolemia

28/03/2023

Lipidomic analysis of adipose-derived extracellular vesicles reveals specific EV lipid sorting informative of the obesity metabolic state

09/12/2022

Impacts of a high-fat diet on the metabolic profile and the phenotype of atrial myocardium in mice

19/05/2022

Plasma FA composition in familial LCAT deficiency indicates SOAT2-derived cholesteryl ester formation in humans

13/04/2022

Phosphatidylserine enhances anti-inflammatory effects of reconstituted HDL in macrophages via distinct intracellular pathways

CERTIFIÉ ISO 9001

Nos soutiens institutionnels

Notre réseau